Provided by Tiger Trade Technology Pte. Ltd.

Xenon Pharmaceuticals

54.87
+0.39000.72%
Volume:158.02K
Turnover:8.66M
Market Cap:5.24B
PE:-12.57
High:55.42
Open:55.06
Low:53.62
Close:54.48
52wk High:63.95
52wk Low:26.74
Shares:95.43M
Float Shares:89.89M
Volume Ratio:0.71
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3646
EPS(LYR):-4.3646
ROE:-51.76%
ROA:-32.58%
PB:9.00
PE(LYR):-12.57

Loading ...

Xenon Pharmaceuticals Inc: Anticipates Submitting New Drug Application for Azetukalner in Fos to U.S. FDA in Q3 2026

THOMSON REUTERS
·
Mar 09

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:58 AM

Reuters
·
Mar 09

Xenon Pharmaceuticals to report Phase 3 X-TOLE2 azetukalner focal seizure trial topline results March 9, 2026

Reuters
·
Mar 09

Xenon to Announce Topline Results From Phase 3 X-Tole2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

THOMSON REUTERS
·
Mar 09

Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)

TIPRANKS
·
Mar 04

A Look At Xenon Pharmaceuticals (XENE) Valuation After Wider Losses And US$400 Million At The Market Offering

Simply Wall St.
·
Mar 01

Xenon Pharmaceuticals XENE Loss Widening Tests Bullish Pipeline Narrative

Simply Wall St.
·
Feb 28

Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program

TIPRANKS
·
Feb 28

Analysts Conflicted on These Healthcare Names: Xenon (XENE), Idexx Laboratories (IDXX) and Warby Parker (WRBY)

TIPRANKS
·
Feb 28

Xenon Pharmaceuticals Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Feb 28

RBC Capital Adjusts Xenon Pharmaceuticals PT to $59 From $58, Maintains Outperform - Speculative Risk Rating

MT Newswires Live
·
Feb 27

Xenon Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 27

Xenon Pharmaceuticals Q4 EPS $(1.31) Misses $(1.19) Estimate

Benzinga
·
Feb 27

Canada's Xenon Pharma reports bigger-than-expected net loss in Q4 due to high R&D expenses

Reuters
·
Feb 27

Xenon posts FY 2025 net loss of USD 345.9 million (47.6%)

Reuters
·
Feb 27

BRIEF-Xenon Pharmaceuticals Q4 Net Income USD -105.261 Million Vs. IBES Estimate USD -95.9 Million

Reuters
·
Feb 27

Xenon Pharmaceuticals options imply 24.8% move in share price post-earnings

TIPRANKS
·
Feb 27

Xenon Pharmaceuticals Initiated at Outperform by Wolfe Research

Dow Jones
·
Feb 24

Xenon (XENE) Receives a Buy from J.P. Morgan

TIPRANKS
·
Jan 20

Xenon Pharmaceuticals Grants Equity Inducement Options to New Employees

Reuters
·
Jan 17